1 active not recruiting, 1 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Terminated 1 |
Follow AZD2811: new trials by email Literature Review of AZD2811 trials Research Report on AZD2811
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of AZD2811 + Durvalumab in ES-SCLC Durvalumab, AZD2811, Carboplatin - Small-Cell Lung Cancer | Phase 2 | Active not recruiting | AstraZeneca | 31 | 2021-02-23 | 2026-07-06 |
| AZD 2811 Monotherapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N3] AZD2811 - Small Cell Lung Cancer | Phase 2 | Terminated | Samsung Medical Center | 15 | 2017-12-01 | 2018-11-27 |
AstraZeneca (1) · Samsung Medical Center (1)
South Korea (2) · Poland (1) · Spain (1) · United States (1)